<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Genta, Sofia</dc:creator>
  <dc:creator>Ghilardi, Guido</dc:creator>
  <dc:creator>Cascione, Luciano</dc:creator>
  <dc:creator>Juskevicius, Darius</dc:creator>
  <dc:creator>Tzankov, Alexandar</dc:creator>
  <dc:creator>Schär, Sämi</dc:creator>
  <dc:creator>Milan, Lisa</dc:creator>
  <dc:creator>Pirosa, Maria Cristina</dc:creator>
  <dc:creator>Esposito, Fabiana</dc:creator>
  <dc:creator>Ruberto, Teresa</dc:creator>
  <dc:creator>Giovanella, Luca</dc:creator>
  <dc:creator>Hayoz, Stefanie</dc:creator>
  <dc:creator>Mamot, Christoph</dc:creator>
  <dc:creator>Dirnhofer, Stefan</dc:creator>
  <dc:creator>Zucca, Emanuele</dc:creator>
  <dc:creator>Ceriani, Luca</dc:creator>
  <dc:date>2022</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Accurate estimation of the progression risk after first-line therapy represents an unmet clinical need in diffuse large B-cell lymphoma (DLBCL). Baseline (18)F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) parameters, together with genetic analysis of lymphoma cells, could refine the prediction of treatment failure. We evaluated the combined impact of mutation profiling and baseline PET/CT functional parameters on the outcome of DLBCL patients treated with the R-CHOP14 regimen in the SAKK38/07 clinical trial (NCT00544219). The concomitant presence of mutated SOCS1 with wild-type CREBBP and EP300 defined a group of patients with a favorable prognosis and 2-year progression-free survival (PFS) of 100%. Using an unsupervised recursive partitioning approach, we generated a classification-tree algorithm that predicts treatment outcomes. Patients with elevated metabolic tumor volume (MTV) and high metabolic heterogeneity (MH) (15%) had the highest risk of relapse. Patients with low MTV and favorable mutational profile (9%) had the lowest risk, while the remaining patients constituted the intermediate-risk group (76%). The resulting model stratified patients among three groups with 2-year PFS of 100%, 82%, and 42%, respectively (p &lt; 0.001).</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://n2t.net/ark:/12658/srd1326726</dc:identifier>
  <dc:identifier>https://susi.usi.ch/global/documents/326726</dc:identifier>
  <dc:identifier>https://susi.usi.ch/documents/326726/files/Ceriani_2022_MDPI_cancers.pdf</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.3390/cancers14041018</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/ark/12658/srd1326726</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>CC BY</dc:rights>
  <dc:source>Cancers. - 2022, vol. 14, p. 1018</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">PET/CT</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Mutational profile</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">DLBCL</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">Lymphoma</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">Prognostic index</dc:subject>
  <dc:subject>info:eu-repo/classification/udc/61</dc:subject>
  <dc:title xmlns:ns6="xml" ns6:lang="en">Integration of baseline metabolic parameters and mutational profiles predicts long-term response to first-line therapy in DLBCL patients : a post hoc analysis of the SAKK38/07 study</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>